logo
The Definition of Transfer learning

The Definition of Transfer learning

Yahoo03-04-2025
Credit - Getty Images
This article is published by AllBusiness.com, a partner of TIME.
Transfer learning is a machine learning technique that allows a model trained on one task to be repurposed or fine-tuned for a related task, drastically reducing the amount of data and computational resources needed.
This method leverages pre-trained models on large datasets to perform well in new, often smaller, domains with limited labeled data. It has become increasingly popular in fields such as natural language processing, computer vision, and speech recognition, where vast amounts of data and time are typically required for training models from scratch.
Pre-trained models: In transfer learning, models are initially trained on large datasets, often unrelated to the target task. For example, models like BERT and GPT-4o in natural language processing are pre-trained on diverse text information.
Fine-tuning: After training on a large dataset, the model is fine-tuned on a smaller, domain-specific dataset. This involves adjusting the weights of the neural network to optimize performance for the new task.
Feature extraction: One key characteristic is that lower layers of a neural network trained on a large dataset capture general features, while higher layers are fine-tuned to specific features related to the target task.
Domain adaptation: Transfer learning allows models to adapt to tasks in a different but related domain. For example, a model trained on general images can be fine-tuned to identify specific objects like medical images or satellite imagery.
Image classification: A model trained on a large image dataset such as ImageNet can be repurposed for a new, smaller dataset.
Natural Language Processing (NLP): In NLP, large models like GPT-4o and BERT are trained on billions of words from the internet. These pre-trained models can then be fine-tuned for specific tasks such as sentiment analysis, question-answering, or text summarization with a much smaller amount of task-specific data.
Speech recognition: A speech recognition system trained on a broad dataset can be fine-tuned for recognizing specific accents or dialects in different languages. For example, a general English speech recognition system could be adapted to recognize Australian English or Indian English with limited labeled data.
Reduced training time: Since the model has already learned general features from the pre-training phase, the training process for a new task is much faster, often requiring fewer resources and less time.
Less data required: Transfer learning allows models to achieve high performance even with a limited amount of labeled data, making it particularly useful in situations where data collection is expensive or time-consuming.
Better performance with small datasets: Transfer learning often results in better performance on smaller datasets than training a model from scratch, because the model has already learned a robust representation from the large dataset.
Cross-domain applicability: It enables the use of knowledge from one domain (e.g., image recognition) to be applied to another related domain (e.g., medical imaging), enabling a wider range of applications for pre-trained models.
Task similarity requirement: Transfer learning works best when the source task (the one used to pre-train the model) is similar to the target task. If the two tasks are very different, transfer learning may not be effective or may even degrade performance.
Overfitting risk: When fine-tuning a model on a small dataset, there is a risk of overfitting, where the model becomes too specialized on the limited new data and fails to generalize well to unseen examples.
Computational resource requirements for pre-training: Although transfer learning reduces the resources needed for fine-tuning, pre-training large models on vast datasets is still computationally expensive and often requires high-performance hardware such as GPUs or TPUs.
Knowledge transfer limitations: Not all knowledge learned from one domain can be transferred effectively to another. For instance, a model trained on natural images may not transfer well to more specialized areas, like recognizing satellite images, where features are quite different.
Transfer learning is a powerful technique in machine learning, allowing models to adapt to new tasks efficiently by leveraging pre-trained knowledge.
This approach not only reduces the need for large amounts of labeled data but also accelerates the development of AI systems across various domains, from healthcare to NLP.
However, it does have its limitations, especially when the source and target tasks are not closely related or when the pre-training phase is highly resource-intensive.
Despite these challenges, transfer learning remains one of the most effective methods for improving model performance and accelerating AI research in numerous fields.
Copyright © by AllBusiness.com. All Rights Reserved
Contact us at letters@time.com.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Levelpath Recognized in the 2025 Gartner® Hype Cycle™ for Procurement and Sourcing Solutions
Levelpath Recognized in the 2025 Gartner® Hype Cycle™ for Procurement and Sourcing Solutions

Business Wire

time34 minutes ago

  • Business Wire

Levelpath Recognized in the 2025 Gartner® Hype Cycle™ for Procurement and Sourcing Solutions

SAN FRANCISCO--(BUSINESS WIRE)-- Levelpath, the leader in AI-native procurement platforms, today announced its inclusion in the 2025 Gartner® Hype Cycle™ for Procurement and Sourcing Solutions. The company was recognized as a Sample Vendor for both Generative AI for Procurement and Intake Management, we believe validating Levelpath's pioneering role in transforming procurement through breakthrough AI innovation. The future of procurement is here, and it is intelligent. While procurement teams have struggled with fragmented data, manual processes, and complex workflows, Levelpath has reimagined what is possible. Built from the ground up for the AI era, their platform goes beyond simple automation by thinking, learning, and evolving with your enterprise. Procurement That Thinks for Itself Levelpath's proprietary Hyperbridge reasoning engine does not just process requests; it understands intent, predicts needs, and orchestrates complex workflows across your entire enterprise. Levelpath's results speak for themselves: Tenfold efficiency gains in sourcing and intake management Up to 70% operational efficiency gains $26 billion in enterprise spend managed through Levelpath Sixty percent reduction in cycle times through intelligent automation Complete visibility across all procurement activities in real-time The New Standard for Procurement Excellence In our opinion, the Gartner Sample Vendor inclusion validates what Levelpath customers already know: AI-native architecture delivers transformational results that retrofitted solutions simply cannot match. Here is how we feel Levelpath redefines procurement excellence: Conversational intelligence: Transform how your teams work. Natural language requests become intelligent actions. No training required. No complex interfaces. Just speak to your procurement platform as you would a trusted colleague. Autonomous operations: Levelpath's AI agents proactively manage supplier onboarding, conduct risk assessments, and ensure compliance before you even know there is an issue. Unified intelligence: One platform. One source of truth. Every supplier, every contract, every decision connected through intelligent automation that eliminates silos and accelerates outcomes. Beyond these core capabilities, Levelpath's AI-native architecture delivers specialized solutions that address procurement's most persistent challenges. Intake Management Revolutionized Levelpath transforms the procurement request experience from frustrating to effortless. Users describe what they need in plain English. The platform's AI interprets, validates, and routes requests through the right approvals automatically, ensuring compliance without compromising speed. "We believe this recognition reaffirms Levelpath's commitment to helping procurement teams navigate complexity with cutting-edge solutions that integrate technology, suppliers and business users," said Alex Yakubovich, CEO of Levelpath. "Our focus on AI-native innovation ensures procurement and the business remain competitive and future-ready in the evolving landscape." Trusted by Industry Leaders Fortune enterprises worldwide, including Ace Hardware, Amgen, Coupang, Fortrea, GATX, SiriusXM, SSM Health, and Western Union, have chosen Levelpath to transform their procurement operations. They have experienced rapid deployment, significant ROI and measurable improvements in productivity and efficiency. The competitive advantage of early AI adoption in procurement has never been clearer. Empowering Procurement Leaders Through AI Education Building on this recognition, Levelpath is launching an AI Masterclass series to accelerate AI adoption across the procurement community. The interactive sessions bring together procurement leaders from Fortune enterprises to share proven use cases, exchange best practices and transform AI curiosity into measurable results. From triaging intake requests in seconds to accelerating contract workflows, each monthly session offers attendees actionable playbooks they can implement immediately, creating a collaborative environment where procurement professionals can experiment, innovate and grow together. The Masterclass series addresses the reality that successful AI implementation in procurement requires more than technology, it demands strategic thinking, operational excellence and community learning. Through live Q&As and peer networking, participants gain insights into how AI is reshaping procurement's ability to deliver value, drive compliance and respond to business needs at unprecedented speed. Whether just beginning their AI journey or seeking to deepen expertise, procurement leaders are using these sessions to evolve from AI-curious operators into AI-powered champions, positioning their organizations for competitive advantage in the intelligent procurement era. Join Levelpath's monthly AI Masterclass series starting Friday, July 25th, featuring SSM Health and other Fortune enterprise leaders as they share proven AI procurement strategies and actionable playbooks you can implement immediately, learn more about this ongoing monthly series and register now to transform your procurement operations. To explore the full landscape of AI innovation in procurement and understand where these transformative technologies are heading, download a complimentary copy of the 2025 Gartner® Hype Cycle™ for Procurement and Sourcing Solutions to learn more about Levelpath's recognition. Gartner, Hype Cycle for Procurement and Sourcing Solutions, 2025, Kaitlynn Sommers, Micky Keck, Lynne Phelan, Cian Curtin, Chaithanya Paradarami, Martin Shreffler, 30 June 2025 *GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and HYPE CYCLE is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. About Levelpath Levelpath is the leading AI-native procurement platform transforming how global enterprises manage indirect spend. Built from the ground up for the AI era, our platform unifies procurement operations through intelligent automation, featuring an intuitive stakeholder interface, advanced workflow orchestration, and our proprietary Hyperbridge reasoning engine that delivers real-time intelligence and complete visibility across all procurement activities. Trusted by leading Fortune enterprises worldwide, including Ace Hardware, Amgen, Coupang, Fortrea, GATX, SiriusXM, SSM Health, and Western Union, Levelpath's AI-native architecture enables organizations to collaborate smarter, operate faster, and scale procurement operations that drive measurable business value. Headquartered in San Francisco, Levelpath is backed by Battery, Benchmark, Redpoint Ventures, 01A, Menlo Ventures, NewView Capital, and World Innovation Lab. Learn more at or connect with us on LinkedIn.

The Dire Wolf Company's Next Target? A Giant Flightless Bird
The Dire Wolf Company's Next Target? A Giant Flightless Bird

Yahoo

timean hour ago

  • Yahoo

The Dire Wolf Company's Next Target? A Giant Flightless Bird

An artist's rendering of a fully grown moa Credit - Colossal Biosciences It has taken no end of imagination for Sir Peter Jackson, the Academy Award winning—and, not incidentally, knighted—director of the Lord of the Rings and Hobbit films, to produce his entire body of cinematic work. It's a quality Jackson has had since he was a small child, when he would conjure up visions of the future. 'When I was a kid [I dreamed of] personal jet packs and flying cars and things,' Jackson said in a recent conversation with TIME. 'One of those other things I always dreamed of was to be able to bring back extinct species.' No-go on the jet packs and the flying cars. But the business of de-extinction? That's very much happening. In April, the Dallas-based biotech company Colossal Biosciences announced that it had successfully brought back the dire wolf, an animal whose howl had not been heard on Earth since the last member of the species vanished more than 10,000 years ago. Three young dire wolves currently live on a 2,000-acre preserve in an undisclosed location to protect them from the media and curiosity-seekers, and Colossal aims to produce more of the animals, with the ultimate goal of perhaps rewilding the species. Read more: The Return of the Dire Wolf The company is not stopping there. Colossal also wants to bring back the dodo, the woolly mammoth, the Tasmanian tiger—or thylacine—and more. The goal is both to increase genetic diversity and to hone genetic editing techniques to fortify existing but threatened species. Now, Colossal has announced one more species to add to its growing menagerie: the emu-like moa, a giant flightless bird that stood up to 12 ft. (3.6 m) tall, tipped the scales at more than 500 lbs (230 kg), and once ranged across New Zealand, before it was hunted to extinction by humans about 600 years ago. Like the moa, Jackson is a native New Zealander; 'I am a very proud kiwi,' he says. He is also a Colossal investor and acted as intermediary and facilitator bringing the company into partnership on the moa project with the Ngāi Tahu Research Center, a group that was founded in 2011 to foster intellectual development and conduct scientific studies for and by the Ngāi Tahu tribe of the Indigenous Māori people. 'Some of those iconic species that feature in our tribal mythology, our storytelling, are very near and dear to us,' says Ngāi Tahu archaeologist Kyle Davis, who is working on the moa de-extinction project. 'Participation in scientific research, species management, and conservation has been a large part of our activities.' 'This is completely a Māori initiative,' adds Ben Lamm, CEO and co-founder of Colossal. 'We feel like the Colossal team is an extension of the research center and the Māori.' Bringing back the moa would have implications not only for the species itself but for the environment it once inhabited and could again. The bird was what is known as a cornerstone species, one whose grazing and browsing helped prune and shape the jungle flora. Moas were also prolific dispersers of seeds from the plants they ate. The loss of the species not only eliminated that forest-restoring function, but also led to the related extinction of the Haast's eagle, which relied almost exclusively on the moa as prey. Restoring the moa would not bring the eagle back but could help at least partly restore the primal New Zealand woodlands. Bringing back the moa is of a piece with Colossal's other work, which seeks not only to restore vanished species, but to prevent related ones from slipping over the event horizon of extinction. Genetic engineering mastered in the dire wolf project, for example, is being used to edit greater diversity into the genome of the endangered red wolf. Knowledge gained in the effort to bring back the thylacine could similarly help preserve the related northern quoll. 'There are some species of birds on the South Island of New Zealand that are endangered due to the fact that they have reduced gene pools,' says Paul Scofield, senior curator of natural history at Canterbury Museum, author of 20 papers on the moa genome, and one of the scientists working on the de-extinction project. 'Some of the technology that Colossal is working with is very applicable to them.' Read more: Scientists Have Bred Woolly Mice on Their Journey to Bring Back the Mammoth That technology is decidedly challenging. De-extincting the dire wolf involved sequencing ancient DNA collected from fossil specimens and then rewriting the genome of cells from a gray wolf to resemble the extinct species with the lost ancient genes. The edited nucleus was then inserted into a domestic dog ovum whose own nucleus had been removed. That ovum was allowed to develop into an embryo in the lab and then implanted into the womb of a surrogate domestic dog, which carried the dire wolf pup to term.' Bringing back the extinct moa is harder since the incubating will be done outside the body, inside an egg. The first step in this work once again calls for sequencing the genome of the extinct target species and once again turning to a closely related living species—either the tinamou or the emu—for help. Colossal scientists will extract primordial germ cells—or cells that develop into egg and sperm—from a tinamou or emu embryo and rewrite their genome to match key features of the moa. Those edited cells will then be introduced into another embryonic tinamou or emu inside an egg. If all goes to plan, the cells will travel to the embryo's gonads, transforming them so that the females produce eggs and the males produce sperm not of the host species but of the moa. The result will be an emu or tinamou that hatches, grows up, mates, and produces eggs containing moa chicks. 'We've had some pretty big successes so far,' says Lamm. 'We have a breeding colony of tinamous but not emus, but have access to emu eggs through the many breeders out there." None of this means that the work is remotely done. Lamm concedes it could be up to ten years before a moa once again walks New Zealand—though it could come sooner. 'I'd rather underpromise and overdeliver,' he says. For now, Colossal and the Ngāi Tahu Research Center are still working to sequence the moa genome, and to do that they have to get their hands on more DNA samples. Museum specimens of moa remains satisfy some of that demand, but DNA degrades significantly over the centuries and what can't be harvested from private collections has to be dug up in field excavations—with a special eye to long, DNA-rich moa bones like the femur and tibia. 'There are a couple of really significant fossil sites, particularly one in North Canterbury, about an hour north of Christchurch,' says Scofield. 'So far we've sampled more than 60 individuals.' If those don't prove sufficient, he adds, 'we will have to go out and dig some more holes.' None of this comes cheap, and while Lamm does not disclose the exact funding for the moa de-extinction project, he does say it is an eight-figure sum. 'I saw the new Jurassic World movie and someone in it says it costs $72 million to bring back one animal,' he says. 'I was like, 'That's probably accurate.'' That up-front expenditure could pay off handsomely down the line, boosting ecotourism to New Zealand and benefiting Colossal's basic research, which is already showing for-profit potential. So far, Colossal has spun off two new companies: One, called Breaking, uses engineered microbes and enzymes to break down plastic waste. The other, Form Bio, provides AI and computational biology platforms for drug development. But it's the intangibles—the wonder of midwifing a long-extinct species back to the global family of extant ones—that is Colossal's and the Māori's most transcendent work. 'This has an excitement value to it that movies don't have,' says Jackson. 'When I see a living moa for the first time I'm going to be absolutely amazed beyond anything I've ever felt.' Write to Jeffrey Kluger at

The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases
The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases

Yahoo

time3 hours ago

  • Yahoo

The $20 Million Bet on CRISPR to Cure Rare Childhood Diseases

Jennifer Doudna, Priscilla Chan Zuckerberg Credit - David Paul Morris—Bloomberg/Getty Images; Suzanne Cordeiro—AFP/Getty Images Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven't been many reliable treatment options for these babies. The few that do exist involve invasive and risky procedures that don't often have a high rate of success. But there is a new source of hope for many of these families: the Center for Pediatric CRISPR Cures at the University of California San Francisco. The center—plans for which were announced July 8—is a collaboration between Jennifer Doudna, director of the Innovative Genomics Institute at the University of California, Berkeley who also earned the Nobel Prize for her work in co-discovering the gene-editing technique CRISPR, and Dr. Priscilla Chan, co-CEO and co-founder of the Chan Zuckerberg Initiative. Supported by $20 million from the Chan Zuckerberg Initiative, the center focuses on treating rare genetic diseases in children, starting with a group of eight kids who will enroll in a clinical trial to access a CRISPR therapy designed specifically for them. Doctors and researchers, including Chan and Doudna, believe that CRISPR can be used to change and correct a range of genetic mutations and scaled up to help more patients. And the medical teams plan to start enrolling patients immediately. "We want to ensure that CRISPR-based therapies become widely available, especially for rare diseases that likely won't be the target for pharmaceutical companies," Doudna tells TIME. Read More: The 4 Words That Drive Your Doctor Up the Wall The partnership was inspired by the recent success in treating KJ Muldoon, the first baby to receive a customized CRISPR treatment. KJ was born at the Children's Hospital of Philadelphia with a rare genetic disease that prevents him from breaking down proteins properly. The therapy, called base-editing, replaced a faulty letter in KJ's DNA with the correct one that now lets him eat some protein. KJ's treatment represents the next phase of CRISPR-based therapies. While CRISPR treatments have been approved by the FDA to treat sickle cell disease and certain types of beta thalassemia, those therapies involve removing cells from patients, editing them with CRISPR to correct the genetic defect, and then infusing those cells back to the patients. In KJ's case, the CRISPR editing occurred in his own body, via three injections of a therapy developed just for him. That's the same model that the new center will use. 'With that story, there was a lot of momentum within our teams about whether we could do that again, and how we could learn from this to create a pipeline to reduce cost and make this therapy much more widely available,' Doudna says. Doudna thought of Chan, whose initiative has the mission of curing, preventing, or treating all diseases by the end of the century. It was an ideal match, since Chan had trained as a pediatrician at the University of California San Francisco and spent eight years treating children with rare genetic diseases after finishing medical school. 'When Jennifer called me, I thought, 'This is perfect,'' Chan tells TIME. She recalls encountering families whose babies were affected by diseases so rare that there was often little, if any, information about them. 'I have seared in my mind the image of a parent handing me a PDF that they carried around to explain to each resident that this is what we have, and this is all that we know about it. I carry that around daily.' The experience inspired her to create the Rare As One program at the Chan Zuckerberg Initiative, a network of patients, researchers, and scientists from different disciplines that highlights the need for basic research needed to better understand these conditions in order to develop more effective treatments for them. Read More: The Surprising Reason Rural Hospitals Are Closing CRISPR, with its ability to target specific genetic mutations, holds the most promise for changing the course of such diseases. But time is of the essence. In KJ's case, the entire process of identifying his mutation, developing the treatment, testing it, and receiving FDA clearance took nine months. KJ was just six months old when he received his first CRISPR treatment. Acting that quickly is critical for conditions like these, since once cells or organs are damaged by disease-causing mutations, they can't always be rescued. The idea is to intervene with a CRISPR therapy to minimize the effects that the mutations could have. Currently, about 6,000 rare diseases affect 300 million people worldwide, and 72% of them are linked to genetic aberrations. A similar proportion primarily affect children. The new center will focus on identifying disease-causing mutations that can easily be targeted—such as in the liver, as in KJ's case. 'Jennifer and her team, and the team at UCSF, will be very careful in choosing mutations that are amenable to this treatment,' says Chan. 'Not all mutations will work well with this version of there will be a delicate balance in choosing patients who stand to benefit the most in this situation.' Patients will join a clinical trial to receive the treatment, and the research team will study them to learn from their experiences and continue to improve the treatment and the process. Read More: Why It's So Hard to Have Your Fertility Tested In the first cases that the center will try to treat, the FDA will consider each treatment on its own and decide whether to approve the customized therapy for that particular patient. But, says Doudna, 'as we continue to get more information on the safety and potential risks of CRISPR for different indications, what is emerging is the potential to designate CRISPR as a platform technology.' That means that if regulators approve the framework of the CRISPR gene-editing process, doctors would not need to conduct animal tests for each new CRISPR therapy designed for a patient. The only thing that would change would be the guide RNA, Doudna says, which carries the genetic instructions for finding the specific mutation that needs to be addressed. 'Even there, most of the guide RNA stays the same, and it's just the piece at the end providing the molecular zip code that changes.' Key to making that happen will be advances in other scientific areas, including using AI to predict how changing specific genes will affect a cell's function and what potential health outcomes a CRISPR-based treatment might have. That work is ongoing separately at places like Chan Zuckerberg Initiative and elsewhere, says Chan. Eventually, says Doudna, 'we hope as the process moves forward, it will be possible to both predict clinical outcomes of CRISPR therapies accurately and ensure that by changing just a little part of the guide RNA, everything else will remain the same, so you don't have to do full-blown animal testing for every single iteration of CRISPR. If that becomes possible, then it will make CRISPR a lot cheaper and a lot faster to test these kinds of therapies.' That would make it available for many more patients as well. Contact us at letters@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store